19 Dec 2023 by admin in UncategorizedComments Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
13 Dec 2023 by admin in UncategorizedComments Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan- inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis
06 Dec 2023 by admin in UncategorizedComments Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
06 Dec 2023 by admin in UncategorizedComments Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC
05 Dec 2023 by admin in UncategorizedComments Adcentrx Announces Extension of Series A+ Financing to $51 Million
05 Dec 2023 by admin in UncategorizedComments Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer
04 Dec 2023 by admin in UncategorizedComments Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer
